Sign in
Not yet recruitingPhase 1/2

Phase 1/2, first-in-human, randomized, double-blind, reference-controlled study to evaluate the safety and immunogenicity of an extemporaneously mixed Combo Inactivated Influenza Vaccine (Green Cross [GC]-IIV; 15µg of each hemagglutinin [HA])/OVX836 (480µg), in comparison to GC-IIV (15µg of each HA) concomitantly administered with OVX836 (480µg), GC-IIV alone (15 µg each HA), OVX836 alone (480µg), and a licensed reference trivalent IIV (Vaxigrip®; 15µg of each HA), administered intramuscularly (IM) in healthy participants

Key facts

Who runs it
Osivax
Where
Belgium1 site in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
250 people, planned
Started
5 Oct 2026
Expected to end
14 May 2027
Type of study
Interventional
Record updated
4 September 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Written informed consent
  • Healthy male or female participants, as determined by medical history and medical examination. Refer to Appendix A for reproductive criteria for male and female participants
  • Participants aged 18 to 49 years, inclusive
  • Reliable and willing to make themselves available for the duration of the study, and willing and able to follow study procedures
  • Ability and technical possibility for completing an eDiary

Who cannot take part

  • Having received another vaccination within 3 months prior to the day of study vaccination for live attenuated vaccines, or within 1 month prior to the day of study vaccination for inactivated vaccines
  • Planning to receive other vaccines during the first 28 days following the study vaccine administration
  • Administration of any investigational or non-registered drug or vaccine within 3 months prior to the administration of study vaccines, or planned administration of any such product during the whole study period
  • History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of vaccination, or planned to receive such product during the whole study period
  • Blood donation ≥450 mL within one month before screening or during study participation
  • Previously exposed to OVX836 vaccine, whatever the dose
  • Past (stopped less than 6 months before enrolment) or current history of alcohol abuse, or current smoking habit above 10 cigarettes per day, or current vaping
  • Treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (>800μg/day beclomethasone or equivalent; occasional inhaled corticosteroids are allowed), radiation treatment, cytotoxic drugs, or current or recent (within 30 days before study entry) chronic or prolonged (>10 days) use of systemic non-steroidal anti-inflammatory drugs, interferon, immunomodulators, allergy shots, as judged by the Investigator
  • History of hypersensitivity or severe allergic reaction to any previous vaccine or hypersensitivity likely to be exacerbated by any component of the study vaccines, in particular egg proteins and/or kanamycin
  • Previous influenza vaccination within 6 months before the day of vaccination or planned to receive during the study duration
  • Presence of an acute illness or febrile episode on the day of vaccination (oral temperature >38.0°C, temporary exclusion criterion)
  • Past or current history of any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome
  • Behavioral or cognitive impairment, or psychiatric disease (depression, mania, bipolar disorder, schizophrenia) that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study
  • Participants with a history of recreational drug use or current use of illicit substances
  • Participants with current or unstable respiratory conditions, including but not limited to asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary hypertension, cystic fibrosis, or acute respiratory infections
  • Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the participants due to participation in the study
  • Any known or suspected immunodeficient conditions
  • Past or current history of autoimmune diseases, as judged by the Investigator
  • Current history of uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases
  • Known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
  • Abnormal safety laboratory parameter(s)
  • Participants with a body mass index (BMI) ≤19 kg/m² or ≥35 kg/m² on the day of vaccination
  • Participant with hyperhydration, hypernatremia, or hyperchloremia
  • Current participation in another clinical study at screening or anticipated participation in another clinical trial during the course of this study
  • Any contraindication to IM administration, as judged by the Investigator
  • Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted, including children of newly composed families
  • Pregnant or lactating woman

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the safety and reactogenicity of the extemporaneously mixed Combo vaccine containing GC-IIV (15µg of each HA) and OVX836 (480µg) administered IM.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from 2026-526939-19-00, who can take part
Record updated
4 September 2026